Welcome to our dedicated page for REGENCY CENTERS SEC filings (Ticker: REGCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REGENCY CENTERS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REGENCY CENTERS's regulatory disclosures and financial reporting.
Regency Centers Corp director Karin Klein acquired additional common stock through equity compensation vesting. On 2026-05-11, 1,807 shares of common stock were delivered upon the exercise or conversion of previously granted awards, rather than through open-market purchases.
The transactions reflect vesting of 1,736 shares of restricted stock under Regency's Omnibus Incentive Plan and settlement of 71 dividend equivalent rights, each equivalent to one common share. After these transactions, Klein directly holds 25,408 shares of Regency Centers common stock.
Regency Centers Corp director Deirdre Evens reported routine equity compensation activity. On May 11, 2026, she exercised derivative awards tied to restricted stock and dividend equivalent rights, converting a total of 1,807 units into common stock at a stated price of $0.00 per share.
Footnotes explain that 1,736 units reflect vesting of a restricted stock grant under Regency's Omnibus Incentive Plan, while 71 units are dividend equivalent rights that accrued as dividends were paid and settled in common shares when the related restricted stock vested. No open-market buys or sales were reported.
Regency Centers Corp director Thomas W. Furphy reported compensation-related equity activity, not open-market trading. On 2026-05-11, he exercised and settled equity awards covering a total of 1,807 shares of Regency common stock through the vesting of restricted stock and related dividend equivalent rights. The footnotes explain that these awards vested under Regency’s Omnibus Incentive Plan, with dividend equivalents converting into common shares as company dividends were paid. The filing shows only derivative exercises and award vesting, with no reported share sales or cash purchases.
Regency Centers Corp director Kristin Ann Campbell increased her direct holdings through equity compensation vesting. On May 11, 2026, she acquired a total of 1,807 shares of common stock via the vesting of restricted stock and settlement of dividend equivalent rights. Following these transactions, she directly owns 6,797 shares of Regency Centers common stock. The footnotes explain that the 1,736 restricted shares vested under Regency’s Omnibus Incentive Plan and 71 dividend equivalents, each equal to one common share, were settled in stock as the related restricted stock vested.
Regency Centers Corp director Gary E. Anderson reported acquiring common stock through equity award vesting. On May 11, 2026, he received 1,807 shares of common stock by exercising or converting previously granted awards.
The filing shows 1,736 shares issued from vesting of restricted stock and 71 shares issued from settlement of dividend equivalent rights. Footnotes explain these arose under Regency’s Omnibus Incentive Plan as compensation, not open-market purchases or sales, and related dividend rights were settled into common stock.
REGENCY CENTERS CORP director James H. Simmons III acquired additional common stock through equity award vesting rather than open-market trading. On May 11, 2026, he exercised and settled equity grants covering 1,807 shares of common stock, consisting of 1,736 restricted stock and 71 dividend equivalent rights under Regency’s Omnibus Incentive Plan. Following these compensation-related transactions, the filing shows he directly owns 8,049 shares of common stock.
BLANKENSHIP C RONALD reported acquisition or exercise transactions in this Form 4 filing.
Regency Centers Corp director C. Ronald Blankenship received 453 shares of Common Stock as compensation. The shares were granted as director's fees paid in stock under Regency's Omnibus Incentive Plan rather than through an open-market purchase. Following this award, Blankenship directly holds 112,804 shares of Regency Centers Common Stock.
Regency Centers Corp director Peter Linneman reported stock-based compensation and a restricted stock conversion. On May 6, 2026, he received 336 shares of common stock as director’s fees paid in stock under Regency’s Omnibus Incentive Plan. The filing also shows the exercise of a Restricted Stock Grant covering 2,150 shares of common stock. These shares vest 100% on May 6, 2027. Following these acquisitions, Linneman directly owns 53,936 shares of Regency Centers common stock, reflecting a routine increase in his equity stake through compensation awards.
REGENCY CENTERS CORP director James H. Simmons III exercised a restricted stock grant for 2,150 shares of common stock. The filing classifies this as a derivative exercise/conversion with no cash price per share, indicating a compensation-related equity award rather than an open‑market trade. Following the transaction, Simmons holds 2,150 shares from this grant directly. According to the footnote, these shares vest 100% on May 6, 2027, meaning they become fully earned on that date if conditions are satisfied.
Regency Centers Corp director Thomas W. Furphy reported a compensation-related equity transaction. He exercised a derivative security labeled as a Restricted Stock Grant to acquire 2,150 shares of Common Stock at a price of $0.00 per share, held directly.
After this transaction, his reported direct holdings of this security total 2,150 shares. A footnote states that these shares vest 100% on May 6, 2027, indicating they are subject to a time-based vesting schedule rather than an open-market purchase or sale.